Giovannini P, Scigliano G, Piccolo I, Soliveri P, Suchy I, Caraceni T
Department of Neurology, Instituto Neurologico C. Besta, Milan, Italy.
Clin Neuropharmacol. 1988 Jun;11(3):201-11. doi: 10.1097/00002826-198806000-00002.
Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.
将平均每日剂量为3毫克的利苏瑞ide给予48例特发性帕金森病患者。20例仅接受利苏瑞ide治疗（A组），36例接受利苏瑞ide+左旋多巴+外周脱羧酶抑制剂治疗（B组）。退出研究主要是因为A组患者缺乏疗效以及B组患者出现精神方面的副作用。在整个4年研究期间持续参与的患者显示出明显改善，且这种改善得以维持。A组患者未出现开关现象或异常不自主运动。
